Aurinia Pharmaceuticals (AUPH) Set to Announce Earnings on Thursday

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) is set to issue its quarterly earnings data before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of $0.02 per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Aurinia Pharmaceuticals Stock Up 1.5 %

Shares of NASDAQ:AUPH opened at $7.32 on Wednesday. Aurinia Pharmaceuticals has a 52-week low of $4.71 and a 52-week high of $10.05. The stock has a market cap of $1.05 billion, a P/E ratio of -21.53 and a beta of 1.45. The business has a fifty day moving average of $7.05 and a two-hundred day moving average of $6.06. The company has a quick ratio of 4.82, a current ratio of 5.33 and a debt-to-equity ratio of 0.18.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on AUPH. Cantor Fitzgerald reissued an “overweight” rating and issued a $10.00 price objective on shares of Aurinia Pharmaceuticals in a report on Monday, September 16th. HC Wainwright reissued a “buy” rating and issued a $13.00 price target on shares of Aurinia Pharmaceuticals in a research note on Friday, September 6th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, Aurinia Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $10.00.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.